

32. (Amended) A mouse comprising a transgene having
the sequence of [Figure 1] SEQ ID NO:1.

Remarks

Applicants request entry of the amendments to the Specification and the claims in order to comply with the objection under the Sequence Rules, as raised in the Office Action of June 20, 2000, and in the pending Office Action of February 20, 2001, Paper 19. Specifically, Applicants have amended the Application to insert a sequence identifier for each of the sequences in the Specification. Applicants assert no new matter is added by these amendments.

Respectfully submitted,



Thomas D. Webster, PhD, JD
Attorney for Applicants
Registration No. 39,872
Phone: 317-276-3334

Eli Lilly and Company
Patent Division/TDW
Lilly Corporate Center
Indianapolis, Indiana 46285

April 12, 2001